Edwards Lifesciences EW Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.09B-73.8% | $1.07B-74.4% | $1.36B-67.2% | $4.14B+182% | $4.18B+196% | ||
| $160.9M+5.0% | $156.6M+0.9% | $156.5M+4.8% | $151.8M+0.1% | $153.3M+3.4% | ||
| $163.3M+3.4% | $158.1M-2.6% | $150.6M-6.5% | $151.5M-0.1% | $157.9M+8.8% | ||
| -$51M-127% | -$52.5M-120% | $9.7M-96.8% | $50.9M-85.0% | $186.7M-42.7% | ||
| $151.4M+93.4% | $395.1M+327% | $226.4M+79.7% | $30.2M-77.2% | $78.3M-23.3% | ||
| —— | —— | —— | —— | $46.8M— | ||
| —— | —— | -$687.9M-463% | -$5.9M+98.5% | $127.6M+136% | ||
| $1.36B— | $1.6B— | —— | —— | —— | ||
| $269.1M+10.7% | $260.2M+3.1% | $212.6M-26.9% | $207M-29.7% | $243.1M-5.3% | ||
| $71.1M— | $64.8M— | $77.2M— | $102.6M— | —— | ||
| $3.1B+102% | $3.09B+244% | $2.65B+409% | $2.16B+52,507% | $1.53B+19,804% | ||
| $56.9M-13.7% | $62.1M+8.0% | $61.3M+7.9% | $64.3M+62.4% | $65.9M+147% | ||
| -$891M— | -$712.9M— | —— | —— | —— | ||
| $1.06B-25.5% | $893.4M-22.9% | $952.9M-36.8% | $1.27B+62.0% | $1.42B+125% | ||
| -$1.2B+9.7% | -$1.01B+0.2% | -$998.1M+29.9% | -$1.23B-109% | -$1.33B-169% | ||
| -$22.4M-300% | -$48.3M-225% | $2.7M— | -$47.8M— | $11.2M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$84.6M-269% | -$132.5M-210% | ||
| $83.9M-73.1% | $117.6M-63.6% | $161.7M-48.9% | $266.7M+11.5% | $311.9M+21.8% | ||
| -$89.8M-31.5% | -$76.5M-108% | -$74.2M-137% | -$74.2M-145% | -$68.3M-1.2% | ||
| $43M— | $23.7M— | —— | —— | —— | ||
| $26.3M+0.4% | $25.9M-6.8% | $25.5M-12.4% | $25.2M-14.9% | $26.2M-10.0% | ||
| —— | —— | —— | -$19.5M-69.6% | -$16.3M-98.8% | ||
| $22.1M-42.4% | $25.1M-45.7% | $49.6M+59.0% | $52.4M— | $38.4M— | ||
| $8.3M— | $7.9M— | $17M— | —— | —— | ||
| $43M-25.7% | $43.3M-5.7% | $52.8M-33.3% | $50.6M-22.2% | $57.9M+5.9% | ||
| $178.3M+128% | $140.9M+124% | $128.4M+199% | $116.1M+102% | $78.3M+56.6% | ||
| $2.7B+83.5% | $2.82B+252% | $2.37B+254% | $1.85B+168% | $1.47B+149% | ||
| -$2.8M-21.7% | -$3.8M-18.8% | -$700K— | -$8.5M— | -$2.3M— | ||
| $193.1M+15.4% | $174.1M-3.0% | $170.4M-7.4% | $170.2M-7.3% | $167.3M-12.0% | ||
| —— | —— | —— | —— | -$3.89B— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $1.06B— | ||
| $1.09B— | $1.34B— | —— | —— | —— | ||
| $1.09B— | $1.34B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Edwards Lifesciences generate?
- Edwards Lifesciences (EW) generated $1.4B in operating cash flow over the trailing twelve months.
- What is Edwards Lifesciences's free cash flow?
- After $269.1M of capital expenditures, Edwards Lifesciences's free cash flow was $1.1B over the trailing twelve months, up 57.5% year over year.
- Where does Edwards Lifesciences's cash flow data come from?
- Every line is extracted from Edwards Lifesciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
